# language_name_wals:	English
# language_name_glotto:	English
# ISO_6393:	eng
# year_composed:	NA
# year_published:	NA
# mode:	written
# genre_broad:	technical
# genre_narrow:	NA
# writing_system:	Latn
# special_characters:	NA
# short_description:	EMEA
# source:	https://object.pouta.csc.fi/OPUS-EMEA/v3/raw/en.zip
# copyright_short:	http://opus.nlpl.eu/EMEA.php
# copyright_long:	http://opus.nlpl.eu/EMEA.php J. Tiedemann, 2012, Parallel Data, Tools and Interfaces in OPUS. In Proceedings of the 8th International Conference on Language Resources and Evaluation (LREC 2012)
# sample_type:	whole
# comments:	NA

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1/ 19 1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 powder and solvent for emulsion for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance Per 1-ml dose:
Canine herpesvirus (F205 strain) antigens............................................. .0.3 to 1.75 µg* *expressed in µg of gB glycoproteins Adjuvant(s) Light paraffin oil...................................................................................................... ..224.8 to 244.1 mg For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder and solvent for emulsion for injection
4.
CLINICAL PARTICULARS
4.1 Target species
Dogs (pregnant bitches)
4.2 Indications for use, specifying the target species
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life.
4.3 Contraindications
None.
4.4 Special warnings
None.
4.5 Special precautions for use
Special precautions for use in animals
Vaccinate only healthy animals.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
To the user:
This product contains mineral oil.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again.
2/ 19 To the physician:
This product contains mineral oil.
Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
4.6 Adverse reactions (frequency and seriousness)
The injection of the vaccine may cause a transient oedema at the site of injection in up to 10% of animals.
These reactions usually regress within one week.
Hypersensitivity reactions may occur.
These are rare and appropriate symptomatic treatment should be administered.
4.7 Use during pregnancy, lactation or lay
Eurican Herpes 205 is specifically indicated during pregnancy.
4.8 Interaction with other medicinal products and other forms of interaction
No information is available on the efficacy from the concurrent use of this vaccine with any other product.
It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with the product.
4.9 Amounts to be administered and administration route
Two 1-ml doses of vaccine, administered by subcutaneous route, according to the following schedule:
First injection:
Either during heat or 7 – 10 days after the presumed date of mating.
Second injection:
1 to 2 weeks before the expected date of whelping.
Revaccination: during each pregnancy, according to the same schedule.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
No undesirable effects other than those observed and mentioned in the “ Adverse reactions” section have been observed after the administration of several doses.
4.11 Withdrawal period(s)
Not applicable.
5.
IMMUNOLOGICAL PROPERTIES
ATCvet code:
QI07AA06
Purified subunit vaccine for the active immunisation of pregnant bitches to induce the passive protection of puppies against herpesvirus-induced fatal neonatal disease.
6.
PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Sucrose Sorbitol Dextran 40
3/ 19 Casein hydrolysate Collagen hydrolysate Salts Polyoxyethylene fatty acids Ether of fatty alcohols and of polyols Triethanolamine
6.2 Incompatibilities
Do not mix with any other immunological product except the solvent supplied.
6.3 Shelf life
24 months.
Use immediately after reconstitution.
6.4.
Special precautions for storage
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
6.5 Nature and composition of immediate packaging
Type I glass bottle containing powder of 1-dose and glass bottle containing 1-ml of solvent.
The bottles are closed with a butyl elastomer closure and sealed with an aluminium cap Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles.
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
7.
MARKETING AUTHORISATION HOLDER
MERIAL 29 Avenue Tony Garnier F-69007 Lyon FRANCE
8.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 01/ 029/ 001- 003
9.
DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
26.03.06
4/ 19 10 DATE OF REVISION OF THE TEXT
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
PROHIBITION OF SALE, SUPPLY AND/ OR USE
Not applicable.
5/ 19 ANNEX II
A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO SAFE AND EFFECTIVE USE
D.
STATEMENT OF THE MRLs
6/ 19 A.
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
Name and address of the manufacturer(s) of the biological active substance(s)
Merial, Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux, 69007 Lyon, France
Name and address of the manufacturer(s) responsible for batch release
MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
B.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION REGARDING SUPPLY OR USE
To be supplied only on veterinary prescription.
C.
CONDITIONS OR RESTRICTIONS OF THE MARKETING AUTHORISATION WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE PRODUCT
Not applicable.
D.
STATEMENT OF THE MRLs
Not applicable.
7/ 19 ANNEX III
LABELLING AND PACKAGE LEAFLET
8/ 19 A.
LABELLING
9/ 19 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 powder and solvent for emulsion for injection
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Per 1-ml dose:
Canine herpesvirus (F205 strain) antigens............................................. .0.3 to 1.75 µg* *expressed in µg of gB glycoproteins Light paraffin oil
3.
PHARMACEUTICAL FORM
Powder and solvent for emulsion for injection.
4.
PACKAGE SIZE
1 dose: powder (1 bottle) + solvent (1 bottle) 50 doses: powder (50 bottles) + solvent (50 bottles)
5.
TARGET SPECIES
Dogs (pregnant bitches)
6.
INDICATION(S)
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Subcutaneous use.
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Not applicable.
10/ 19 9.
SPECIAL WARNING(S), IF NECESSARY
Accidental injection is dangerous – read the package leaflet before use.
10.
EXPIRY DATE
EXP {month/ year} Use immediately after reconstitution.
11.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Read the package leaflet before use.
13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MERIAL 29 Avenue Tony Garnier F-69007 Lyon France
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 01/ 029/ 002 50 doses: powder (50 bottles) + solvent (50 bottles) EU/ 2/ 01/ 029/ 003 1 dose: powder (1 bottle) + solvent (1 bottle)
17.
MANUFACTURER’ S BATCH NUMBER
Lot
11/ 19 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 powder and solvent for emulsion for injection
2.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Per 1-ml dose:
Canine herpesvirus (F205 strain) antigens............................................. .0.3 to 1.75 µg* *expressed in µg of gB glycoproteins Light paraffin oil
3.
PHARMACEUTICAL FORM
Powder and solvent for emulsion for injection.
4.
PACKAGE SIZE
10 doses: powder (10 bottles) + solvent (10 bottles)
5.
TARGET SPECIES
Dogs (pregnant bitches)
6.
INDICATION(S)
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life.
7.
METHOD AND ROUTE(S) OF ADMINISTRATION
Subcutaneous use.
Read the package leaflet before use.
8.
WITHDRAWAL PERIOD
Not applicable.
9.
SPECIAL WARNING(S), IF NECESSARY
Accidental injection is dangerous – read the package leaflet before use.
12/ 19 10.
EXPIRY DATE
EXP {month/ year} Use immediately after reconstitution.
11.
SPECIAL STORAGE CONDITIONS
Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
12.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY
Read the package leaflet before use.
13.
THE WORDS “ FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only - to be supplied only on veterinary prescription.
14.
THE WORDS “ KEEP OUT OF THE REACH AND SIGHT OF CHILDREN”
Keep out of the reach and sight of children.
15.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
MERIAL 29 Avenue Tony Garnier F-69007 Lyon France
16.
MARKETING AUTHORISATION NUMBER(S)
EU/ 2/ 01/ 029/ 001 10 doses: powder (10 bottles) + solvent (10 bottles)
17.
MANUFACTURER’ S BATCH NUMBER
Lot
13/ 19 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 powder for injection
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
Read the package leaflet before use
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 dose
4.
ROUTE(S) OF ADMINISTRATION
SC
5.
WITHDRAWAL PERIOD
Withdrawal period:
Not applicable.
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP {month/ year} Use immediately after reconstitution.
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
14/ 19 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
{NATURE/ TYPE}
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 solvent
2.
QUANTITY OF THE ACTIVE SUBSTANCE(S)
Read the package leaflet before use
3.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
1 ml
4.
ROUTE(S) OF ADMINISTRATION
SC
5.
WITHDRAWAL PERIOD
Withdrawal period:
Not applicable.
6.
BATCH NUMBER
Lot
7.
EXPIRY DATE
EXP {month/ year} Use immediately after reconstitution.
8.
THE WORDS “ FOR ANIMAL TREATMENT ONLY”
For animal treatment only.
15/ 19 B.
PACKAGE LEAFLET
16/ 19 PACKAGE LEAFLET Eurican Herpes 205 powder and solvent for emulsion for injection
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder:
MERIAL, 29 Avenue Tony Garnier, F-69007 Lyon, France
Manufacturer for the batch release:
MERIAL, Laboratoire Porte des Alpes, Rue de l’ Aviation, F-69800 Saint Priest, France
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Eurican Herpes 205 powder and solvent for emulsion for injection
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
Per 1-ml dose:
Canine herpesvirus (F205 strain) antigens............................................. .0.3 to 1.75 µg* *expressed in µg of gB glycoproteins Light paraffin oil
4.
INDICATION(S)
Active immunisation of bitches to prevent mortality, clinical signs and lesions in puppies resulting from canine herpes virus infections acquired in the first few days of life.
5.
CONTRAINDICATIONS
None.
6.
ADVERSE REACTIONS
Hypersensitivity reactions may occur.
These are rare and appropriate symptomatic treatment should be administered.
The injection of the vaccine may cause a transient oedema at the site of injection in up to 10% of animals.
These reactions usually regress within one week.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
7.
TARGET SPECIES
Dogs (pregnant bitches)
17/ 19 8.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
Two 1-ml doses of vaccine, administered by subcutaneous route, according to the following schedule:
First injection:
Either during heat or 7 – 10 days after the presumed date of mating.
Second injection:
1 to 2 weeks before the expected date of whelping.
Revaccination: during each pregnancy, according to the same schedule.
9.
ADVICE ON CORRECT ADMINISTRATION
None.
10.
WITHDRAWAL PERIOD
Not applicable
11.
SPECIAL STORAGE PRECAUTIONS
Keep out of the reach and sight of children Store in a refrigerator (2 °C – 8 °C).
Do not freeze.
Protect from light.
Use immediately after reconstitution.
Do not use after the expiry date stated on the label.
12.
SPECIAL WARNING(S)
• Vaccinate only healthy animals. • Do not mix with any other immunological product except the solvent supplied. • Eurican Herpes 205 is specifically indicated during pregnancy. • No information is available on the efficacy from the concurrent use of this vaccine with any other product.
It is therefore recommended that no other vaccines should be administered within 14 days before or after vaccination with the product • No undesirable effects other than those observed and mentioned in the “ Adverse reactions” section have been observed after the administration of several doses. • To the user:
This product contains mineral oil.
Accidental injection/ self injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
If you are accidentally injected with this product, seek prompt medical advice even if only a very small amount is injected and take the package insert with you.
If pain persists for more than 12 hours after medical examination, seek medical advice again. • To the physician:
This product contains mineral oil.
Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit.
Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.
18/ 19 13.
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with the local requirements.
14.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
Detailed information on this product is available on the website of the European Medicines Agency (EMEA) http: / /www. emea. eu. int/
15.
OTHER INFORMATION
Purified subunit vaccine for the active immunisation of pregnant bitches to induce the passive protection of puppies against herpesvirus-induced fatal neonatal disease.
Box of 2 x 1 bottle, 2 x 10 bottles and 2 x 50 bottles.
Not all pack sizes may be marketed.
To be supplied only on veterinary prescription.
19/ 19